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Table 1: Characteristics of participants at baseline  
Values are mean ± SD, unless stated otherwise 
 
Variables Control Intervention        All 
N 28 30 58 
Age (years) 30.8 + 9.3 33.8 + 11.4 32.3 + 10.5 
Male sex  24 (86%) 15 (50%) 39 (67%) 
White  25 (89%) 29 (97%) 54 (93%) 
BMI (kg/m
2
) 24.7 + 4.2 24.8 + 3.4 24.8 + 3.8 
HbA1c (% (mmol/mol)) 9.0 + 2.3  
(75 + 25) 
9.0 + 2.3  
(75 + 25) 
9.0 + 2.3  
(75 + 25) 
Total insulin dose (U/Kg) 0.33 + 0.20 0.30 + 0.25 0.31 + 0.22 
AUC C-peptide (pmol/L)
1
 993 ± 929 780 ± 308 883 ± 685 
Predicted VO2max (ml/kg/min) 35.1 ± 9.56 32.2 ± 5.6 33.6 ± 7.9 
Presentation of diabetes     
- Duration of symptoms (days) 15 + 38 10  + 10 12 + 27 
- DKA at diagnosis  (%) 3 (11) 8 (27) 11 (19) 
N
o
 without any islet antibodies (%) 11 (39) 3 (10) 14 (24) 
GAD-titre positive (%) 14 (50) 26 (87) 40 (69) 
I2A-titre positive (%) 12 (43) 14 (47) 26 (45) 
Znt8-titre positive (%) 10 (36) 13 (43) 23 (40) 
 
1
One participant had very large C-peptide AUC value for all three visits, which inflated the standard 
deviation in the Control group. However, this did not cause major concern for the final C-peptide 
regression model as the residual was minimal. 
 
